Beam Therapeutics
BEAM
20.90
-0.04
-0.19%
Beam Therapeutics
US · BEAM
#2614 by market cap
Listed 2020
20.90
-0.04
-0.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
About Beam Therapeutics
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
- Founded
- 2017
- CEO
- Mr. John Evans
- Employees
- 511
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- beamtx.com
Company profile
- Exchange
- US
- Symbol
- BEAM
- Market-cap rank
- #2614
- Listing date
- 2020-02-06
- Market cap
- 2.16B
- Float cap
- 1.92B
- Shares out
- 103.50M
- Float shares
- 91.86M
Sectors & themes
Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.
Beam Therapeutics discussion 0 comments